advertisement

Topcon

11.13.5 Other (99)

Showing records 1 to 25

Display only abstracts from IGR 22-2 in classification 11.13.5 Other

Search within classification 11.13.5 Other

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Bengtsson B; Lindén C; Heijl A; Andersson-Geimer S; Andersson-Geimer S; Aspberg J; Aspberg J; Aspberg J; Jóhannesson G
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)


92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Prager AJ; Tang M; Pleet AL; Petito LC; Tanna AP
Ophthalmology. Glaucoma 2021; 4: 597-603 (IGR: 22-1)


86422 Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Asrani S
Advances in Therapy 2020; 37: 1620-1631 (IGR: 21-2)


86579 Reversible Corneal Endothelial Abnormalities With Netarsudil
Tanna AP; Esfandiari H
Journal of Glaucoma 2020; 29: e41-e43 (IGR: 21-2)


86422 Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Bacharach J; Holland E
Advances in Therapy 2020; 37: 1620-1631 (IGR: 21-2)


86579 Reversible Corneal Endothelial Abnormalities With Netarsudil
Teramoto K
Journal of Glaucoma 2020; 29: e41-e43 (IGR: 21-2)


86422 Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Advances in Therapy 2020; 37: 1620-1631 (IGR: 21-2)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Wisely CE
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


85183 Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
Wang N
Clinical Ophthalmology 2020; 14: 221-230 (IGR: 21-1)


85153 The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis
Xing Y
PLoS ONE 2020; 15: e0229682 (IGR: 21-1)


84761 Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Aref AA
Expert Review of Clinical Pharmacology 2019; 12: 1073-1079 (IGR: 21-1)


84729 Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
Lerner SF
Clinical Ophthalmology 2019; 13: 2411-2419 (IGR: 21-1)


84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Mehran NA
Eye 2020; 34: 72-88 (IGR: 21-1)


85136 Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Belfort R; Paula JS
Clinical Therapeutics 2020; 42: 263-275 (IGR: 21-1)


84761 Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Geyman LS
Expert Review of Clinical Pharmacology 2019; 12: 1073-1079 (IGR: 21-1)


84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Sinha S
Eye 2020; 34: 72-88 (IGR: 21-1)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Sheng H
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


84729 Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
Oddone F
Clinical Ophthalmology 2019; 13: 2411-2419 (IGR: 21-1)


85153 The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis
Zhu L
PLoS ONE 2020; 15: e0229682 (IGR: 21-1)


85183 Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
Lu DW
Clinical Ophthalmology 2020; 14: 221-230 (IGR: 21-1)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Heah T
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


85183 Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
Pan Y
Clinical Ophthalmology 2020; 14: 221-230 (IGR: 21-1)


84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Razeghinejad R
Eye 2020; 34: 72-88 (IGR: 21-1)


84729 Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
Lu DW
Clinical Ophthalmology 2019; 13: 2411-2419 (IGR: 21-1)


85136 Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Lopes Silva MJ
Clinical Therapeutics 2020; 42: 263-275 (IGR: 21-1)



Issue 22-2

Change Issue


advertisement

Oculus